Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01EUF
|
|||
| Former ID |
DCL000003
|
|||
| Drug Name |
BMS 275291
|
|||
| Synonyms |
D 2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; (2S)-N-[(2S)-3,3-dimethyl-2-(methylamino)butanoyl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Kaposi sarcoma [ICD-11: 2B57] | Discontinued in Phase 3 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Discontinued in Phase 3 | [1] | ||
| Prostate cancer [ICD-11: 2C82.0] | Discontinued in Phase 3 | [1] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bristol Myers Squibb; Celltech Group
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H41N5O5S
|
|||
| Canonical SMILES |
CC(C)CC(C(=O)NC(=O)C(C(C)(C)C)NC)NC(=O)C(CCN1C(=O)C(N(C1=O)C)(C)C)S
|
|||
| InChI |
1S/C23H41N5O5S/c1-13(2)12-14(17(29)26-19(31)16(24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,24,34H,10-12H2,1-9H3,(H,25,30)(H,26,29,31)/t14-,15-,16+/m0/s1
|
|||
| InChIKey |
BWLOJMZLTBBDHA-HRCADAONSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8. | |||
| REF 2 | Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer. 2004 Dec;46(3):361-8. | |||
| REF 3 | Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol. 2005 Apr 20;23(12):2831-9. | |||
| REF 4 | Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.